广西医学Issue(7)：834-837,4.DOI:10.11675/j.issn.0253-4304.2013.07.07
尼妥珠单抗联合同步放化疗治疗局部晚期鼻咽癌的疗效观察▲
Effect of Nimotuzumab Combined with Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
摘要
Abstract
Objective To investigate the safety and efficacy of nimotuzumab combined with concurrent che-moradiotherapy for locally advanced nasopharyngeal carcinoma .Methods Forty untreated cases of III-Ⅳa stage naso-pharyngeal undifferentiated non-keratinizing carcinoma were divided into two groups according to their first visit date , 20 cases in each group.The treatment group was given nimotuzumab (intravenous infusion of 100mg once a week),and the treatment lasted for 6-8 weeks;Conformal intensity modulated radiotherapy combined with concurrent CF chemo-therapy was performed in the treatment group for 2 to 6 cycles.Conformal intensity modulated radiotherapy combined with CF chemotherapy was performed in the control group ,the same as in the treatment group .Immunohistochemistry was used to detect epidermal growth factor receptor ( EGFR) in tumor tissues while in situ hybridization assay was used to detect EBER expression .The safety and efficacy of treatment were evaluated 3,6 and 12 months after treatment,re-spectively.Results The positive rates of EGFR expression in the treatment group and control group were 90.0%and 100.0%,respectively.The positive rate of EBER expression was 100.0%in the two groups.There was no significant difference in the positive rates of EGFR and EBER expression between two groups (P>0.05).The efficacy of treat-ment for treatment group was superior to that for control group 3 months after treatment as well as 6 months after treat-ment( P<0.05 );There was no significant difference in the severity of adverse reaction between two groups during treatment period (P>0.05).Conclusion The positive rate of EGFR expression in the nasopharyngeal undifferentiat-ed non-keratinizing carcinoma is high .Nimotuzumab combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma can improve the efficacy ,its adverse reactions are similar with those of concurrent chemora-diotherapy ,and patient tolerance is good .关键词
鼻咽肿瘤/表皮生长因子受体/尼妥珠单抗/放射疗法/化学疗法Key words
Nasopharyngeal tumor/Epidermal growth factor receptor/Nimotuzumab/Radiotherapy/Chemo-therapy分类
医药卫生引用本文复制引用
何宁,司勇锋,孙金杰,翁敬锦,覃扬达,韦海明,兰桂萍,王勇利,李冰..尼妥珠单抗联合同步放化疗治疗局部晚期鼻咽癌的疗效观察▲[J].广西医学,2013,(7):834-837,4.基金项目
广西卫生厅重点科研课题 （）
